Study Design

Randomized, Controlled, Two Arm , Open label

Study Population

Patients with metastatic adenocarcinoma of the pancreas  treated with standard of care Gemcitabine

Participating Centers

Hadassah Medical Center, Tel Aviv Sourasky Medical Center, Assaf Harofeh Medical Center, Rambam Health Care Campus, Emek Medical Center, Sheba Medical Center, Soroka Medical Center, Hillel Yaffe Medical Center, Clinical Center of Serbia, Clinical Hospital Center “Bezanijska Kosa”


All Patients on Gemcitabine, with or w/o TL-118

Sample Size

100 patients (50 patients per arm), active but not recruiting

Study Endpoints

• Primary: Disease Control Rate (DCR) measured at 16 weeks

• Secondary: OS, RR, PFS, QoL, Safety &Tolerability

Built by

© copyright 2015 Tiltan Pharma